A

Aytu BioPharma

AYTU

2.60000
USD
-0.05
(-1.89%)
Market Closed
Volume
113
EPS
0
Div Yield
0
P/E
-1
Market Cap
13,198,843
Related Instruments
A
ALT
-0.27000
(-4.24%)
6.10000 USD
B
BCRX
-0.19000
(-2.61%)
7.10000 USD
C
CODX
-0.03000
(-2.59%)
1.13000 USD
I
INO
-0.670
(-6.28%)
10.000 USD
MRNA
-25.020
(-20.99%)
94.160 USD
N
NVAX
-0.250
(-1.95%)
12.560 USD
O
OPK
-0.05000
(-3.50%)
1.38000 USD
REGN
13.14
(1.22%)
1,091.19 USD
V
VXRT
-0.01170
(-1.74%)
0.65890 USD
News

Title: Aytu BioPharma

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidityand a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.